CTXR Earnings & Financial Statements
Citius Pharmaceuticals, Inc.
$0.47
-$0.01(-2.31%)
30
Overall
60
Value
10
Tech
21
Quality
Market Cap
$12.77M
Volume
233.51K
52W Range
$0.47 - $2.19
Target Price
$4.00
CTXR earnings and financial statements: Citius Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CTXR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $90.0K | $90.0K |
| Operating income | -$38.53M | -$42.00M | -$36.73M | -$33.32M | -$23.53M |
| EBITDA | -$38.20M | -$39.69M | -$32.92M | -$33.14M | -$22.88M |
| Net income | -$37.43M | -$40.19M | -$33.69M | -$33.64M | -$23.05M |
| EPS (diluted) | $-3.38 | $-5.97 | $-5.50 | $-5.75 | $-5.75 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $130.94M | $116.65M | $103.61M | $114.00M | $142.43M |
| Total liabilities | $53.41M | $42.55M | $12.18M | $10.57M | $9.65M |
| Shareholders’ equity | $67.55M | $70.08M | $90.83M | $102.83M | $132.18M |
| Cash and equivalents | $4.25M | $3.25M | $26.48M | $41.71M | $70.07M |
| Long-term debt | $724.9K | $21.3K | $262.9K | $481.2K | $678.2K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$24.25M |
| Capital expenditure | -$5.75M | -$5.00M | - | - | -$40.01M |
| Free cash flow | -$32.30M | -$33.20M | -$29.06M | -$28.36M | -$64.26M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTXR | $0.47 | -2.3% | 233.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Citius Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW